Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Pancreatic Adenocarcinoma: early-phase trial registry
11 of 38 indexed Metastatic Pancreatic Adenocarcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #393 of 28,707 conditions by registered trial count.
38 US clinical trials · 11 currently recruiting · #393 of 28,707 conditions by registered trial count
Metastatic Pancreatic Adenocarcinoma: 38 US clinical trials tracked, 11 recruiting.
Metastatic Pancreatic Adenocarcinoma is the subject of 38 registered US clinical trials on ClinicalTrials.gov, 11 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 33 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 7 of these trials.
Enrollment posture brief
Registry condition metastatic-pancreatic-adenocarcinoma
OPEN 11 | RECR 29% | LATE 3 | EARLY 33 | RANK #393 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Obesity (29% recruiting · 1,057 trials)
Metastatic Pancreatic Adenocarcinoma lists 11 open slots (29% of 38 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastatic Pancreatic Adenocarcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastatic Pancreatic Adenocarcinoma is recruiting below its size-band peers.
11 of 38 indexed trials (28.9%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Metastatic Pancreatic Adenocarcinoma research.
National Cancer Institute (NCI) accounts for 7 of 38 trials (18.4%). 24 distinct sponsors appear on at least one study for this condition label.
-
Most Metastatic Pancreatic Adenocarcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 48 among the 38 trials that report a genuine target (sentinel values excluded). 31 of those (81.6%) plan for fewer than 100 participants.
-
Metastatic Pancreatic Adenocarcinoma research is mostly interventional.
38 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
38 total, page 1 of 1
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Astellas Pharma Global Development
NCT07409272
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
Eleison Pharmaceuticals
NCT01954992
Telehealth Self-Management Coaching Sessions to Improve Quality of Life in Pancreatic Cancer Survivors and Their Family Care Givers
City of Hope Medical Center
NCT06524973
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
SWOG Cancer Research Network
NCT06998940
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
Anne Noonan
NCT04115163
Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma
Medical University of South Carolina
NCT07076212
TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma
University of California, Davis
NCT07189195
BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma
Mayo Clinic
NCT07226856
Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer
Barbara Ann Karmanos Cancer Institute
NCT06576115
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
M.D. Anderson Cancer Center
NCT03608631
Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
Mayo Clinic
NCT06381154
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
Astellas Pharma Global Development
NCT03816163
Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread
ECOG-ACRIN Cancer Research Group
NCT04233866
FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
NCT02890355
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
National Cancer Institute (NCI)
NCT02498613
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
NCT01585805
Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations
National Cancer Institute (NCI)
NCT04548752
A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma
CG Pharmaceuticals
NCT05249101
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
Emory University
NCT03368963
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
University of Southern California
NCT02495896
Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
University of Southern California
NCT03257761
Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma
Vaccinex
NCT05102721
LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy
Georgetown University
NCT02985125
Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer
M.D. Anderson Cancer Center
NCT04132505
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer
National Cancer Institute (NCI)
NCT04514497
BATs Treatment for Pancreatic Cancer, Phase Ib/II
University of Virginia
NCT03269526
Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT01660971
Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer
Academic and Community Cancer Research United
NCT03337087
Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
Memorial Sloan Kettering Cancer Center
NCT05642962
Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
OHSU Knight Cancer Institute
NCT05034627
Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors
National Cancer Institute (NCI)
NCT04616534
A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer
Astellas Pharma Global Development
NCT06396091
FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01896869
Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03006302
Medical Food for the Dietary Management of Advanced/Metastatic Pancreatic Cancer
Faeth Therapeutics
NCT05078775
Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma
Clovis Oncology
NCT01233375
Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer
Emory University
NCT04524702
BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer
Barbara Ann Karmanos Cancer Institute
NCT02620865
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 18 |
| Phase 2 | 15 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastatic Pancreatic Adenocarcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastatic Pancreatic Adenocarcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastatic Pancreatic Adenocarcinoma page
38 registered trials, 11 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 11 Metastatic Pancreatic Adenocarcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Metastatic Pancreatic Adenocarcinoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Pancreatic Adenocarcinoma condition card totals 38 registered trials; most-linked intervention Gemcitabine; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.